Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab maintenance after autologous transplant in peripheral T-cell lymphoma
2006-001164-24Phase 2Terminated
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in peripheral T-cell lymphoma (PTCL), sponsored by Gruppo Italiano Studio Linfomi. Primary endpoint: Progression-free survival. Started Aug 2006; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2006-001164-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001164-24.